Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical metformin versus triple combination cream for melasma
IRCT20210823052264N9Phase 3Completed
- Sponsor
- Combined Military Hospital Quetta
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of metformin, tretinoin, hydroquinone and fluocinolone in melasma (2 arms), sponsored by Combined Military Hospital Quetta. Primary endpoints: Safety and efficacy and Melasma Area and Severity Index. Started Sep 2024; status: completed.
02
Drugs
metformintretinoinhydroquinonefluocinolone
03
Conditions
melasma
Beyond the preview
Go deeper on IRCT20210823052264N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210823052264N9.